Skip to main content

Oral Drug Product Use in the Elderly Patient Population

  • Chapter
  • First Online:
Developing Drug Products in an Aging Society

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

Abstract

This chapter explores in detail the many considerations to be factored into the design of oral drug product s for use in the elderly patient . These considerations include characteristics of the dose form and holistic drug product, as well as characteristics of the intended patient population. These characteristics are detailed and discussed. For synthetically manufactured drug substances, oral administration is the most frequent and popular drug administration route used in medical practice today. Subsequently, drug products designed to be administered by the oral route are the most common dosage forms available worldwide. The popularity of the oral route is a result of a number of inherent advantages, and these advantages impact all key stakeholders in the pharmaceutical paradigm, including patients, healthcare providers, manufacturers, and regulators. A few of the advantages of oral drug products over alternative routes of delivery include self-administration, dose accuracy and uniformity, stability, portability, lack of invasiveness, familiarity to patients, and relatively low cost to manufacture. Additionally, to have the best chance at designing an outstanding product, gaining a comprehensive understanding of the target customer behaviors and needs, and incorporating that knowledge into the product design, is a must. The evolution toward drug products that are intentionally designed to meet not only their safety, efficacy and quality requirements, but also provide opportunity for improved outcomes through better patient experience and improved adherence should enhance overall therapeutic outcomes. When designing for an elderly target patient population, the drug product designer and developer should pay particular attention to the specific characteristics of the disease state, target patient population, comorbidities and other emotional, environmental, and sociological factors that have the potential to impact or interfere with the elderly patient’s ability to use the product as intended. Failure to take a diligent approach in this regard can result in a greater likelihood of poor adherence and improper usage of the drug product, resulting in lower effectiveness, poor therapeutic outcomes, and potential safety risks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Quillivant XR, Quillavant XR is a Registered Trademark of Pfizer Inc.

  2. 2.

    Prevalence of Age-Related Macular Degeneration in the United States, The Eye Diseases Prevalence Research Group, Arch Ophtalmol. 2004;122:564–572.

  3. 3.

    Guidance for Industry: Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products; U.S. Dept. of Health and Human Services, Food and Drug Administration (CDER); May 2011.

  4. 4.

    Aricept® Oral Jelly is a registered trademark of Eisai Co. Ltd.

  5. 5.

    Draft Guidance for Industry and Food and Drug Administration Staff: Applying Human factors and Usability Engineering to Medical Devices; U.S. Dept. of Health and Human Services, Food and Drug Administration (CDRH); February 3, 2016.

  6. 6.

    Guidance for Industry (Draft): Safety Considerations for Product Design to Minimize Medication Errors; U.S. Dept. of Health and Human Services, Food and Drug Administration (CDER); December 2012.

References

  1. Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy, 3rd ed., 1986.

    Google Scholar 

  2. Patient Adherence: The Next Frontier in Patient Care; Vision and Reality, 9th Edition; Global Research Report by Capgemini Consulting, 2011.

    Google Scholar 

  3. Cooper, Vanessa; From Hospital to Home: The Changing Therapeutic Area of Oncology, Adherence Researchâ„¢ Summarized; Atlantis Healthcare, 2013.

    Google Scholar 

  4. Charlesworth et al. Polypharmacy among adults age 65 years and older in the United States: 1988–2010, J Gerontolog A Biol Sci Med Sci. 2015;989–95.

    Google Scholar 

  5. Ben Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002;31:285–93.

    Google Scholar 

  6. Stegemann S, et al. Geriatric drug therapy: neglecting the inevitable majority. Aging Res Rev. 2010;9:384–98.

    Article  Google Scholar 

  7. Sampson EL et al. Enteral tube feeding for older people with advanced dementia (review). The Cochrane Collaboration; 2009.

    Google Scholar 

  8. Garin N, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci. 2016;71(2):205–14.

    Article  PubMed  Google Scholar 

  9. Chen PH, et al. Prevalence of perceived dysphagia and quality-of-life impairment in a geriatric population. Dysphagia. 2009;24(1):1–6.

    Article  PubMed  Google Scholar 

  10. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430(1):197–206.

    Article  CAS  PubMed  Google Scholar 

  11. Liu F et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs 74.16 2014:1871–89.

    Google Scholar 

  12. Hey H, et al. Esophageal transit of six commonly used tablet and capsules. Br Med J. 1982;285:717.

    Article  Google Scholar 

  13. Slavkova, et al. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015;75:2–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert L. Ternik .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Ternik, R.L. (2016). Oral Drug Product Use in the Elderly Patient Population. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_15

Download citation

Publish with us

Policies and ethics